AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BLACKSTONE MINERALS LTD

0.038

0.000

Volume:8

Turnover:0.30

Market Cap:65.34M

PE:-3.04

High:0.038

Open:0.038

Low:0.038

Close:0.038

52wk High:0.086

52wk Low:0.028

Shares:1.72B

Float Shares:1.38B

Volume Ratio:0.00

T/O Rate:NaN%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.013

EPS(LYR):-0.016

ROE:-13.57%

ROA:-6.86%

PB:0.75

PE(LYR):-2.35

Loading ...

Overview Company News Filings

How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific (BSX) Has Changed Its Investment Story

Simply Wall St.

Is Boston Scientific (BSX) Undervalued Following Its Russell Growth Index Removal?

Simply Wall St.

Australia's Anson Resources Gains Most in a Month on U.S Lithium Operations Approval

ASX Penny Stocks To Watch In July 2026

Simply Wall St.

How Softer 2026 Guidance and EP Share Shifts At Boston Scientific (BSX) Has Changed Its Investment Story

Simply Wall St.

Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance

Simply Wall St.

Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength?

Simply Wall St.

Blackstone Minerals Ltd-Key Consultants Appointed as Mankayan Pfs Gains Moment

THOMSON REUTERS

Assessing Boston Scientific (BSX) Valuation After Strong SEISMIQ 4CE Trial Results

Simply Wall St.

Boston Scientific's 2026 Guidance Intact Despite Watchman Headwind, RBC Capital Markets Says

MT Newswires Live

Top Midday Decliners

MT Newswires Live

Boston Scientific Shares Fall as CEO Flags Short-Term Challenges

MT Newswires Live

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

MT Newswires Live

Boston Scientific Catheter Says Trial Meets Safety, Effectiveness Goals

MT Newswires Live

Boston Scientific Makes Third Attempt at TAVR Market, Needham Says

MT Newswires Live

Penumbra is a 'Strong' Strategic fit for Boston Scientific, RBC Says

MT Newswires Live

Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed

Simply Wall St.

Boston Scientific 2026 Guidance Cut 'Prudent,' Q2 Trough Expected, RBC Says

MT Newswires Live

GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.34 to $3.41, vs. FactSet Est of $3.45

MT Newswires Live

A Look At Boston Scientific (BSX) Valuation After Recent Share Price Weakness And Penumbra Deal Impact

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BSX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","market":"AU","secType":"STK","nameCN":"BLACKSTONE MINERALS LTD","latestPrice":0.038,"timestamp":1790921520000,"preClose":0.038,"halted":0,"volume":8,"delay":0,"changeRate":0,"nameEN":"BLACKSTONE MINERALS LTD","floatShares":1378369438,"shares":1719359861,"eps":-0.012512,"marketStatus":"Market Closed","change":0,"latestTime":"10-02 16:12:00 AEST","open":0.038,"high":0.038,"low":0.038,"amount":0.304,"amplitude":0,"askPrice":0.038,"askSize":14552,"bidPrice":0.035,"bidSize":785064,"shortable":3,"etf":0,"ttmEps":-0.012512,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.038,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":0.000014258216293075291,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BSX.AU","preClose":0.038,"auctionPrice":0.038,"auctionVolume":8,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921282058}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","floatShares":1378369438,"roa":"-6.86%","roe":"-13.57%","lyrEps":-0.01616,"volumeRatio":0.000014258216293075291,"shares":1719359861,"dividePrice":0,"high":0.038,"amplitude":0,"preClose":0.038,"low":0.038,"week52Low":0.028,"pbRate":"0.75","psRate":"160.89","week52High":0.086,"institutionHeld":0,"latestPrice":0.038,"committee":0.963603,"eps":-0.012512,"divideRate":0,"volume":8,"delay":0,"ttmEps":-0.012512,"open":0.038,"prevYearClose":0.055,"prevWeekClose":0.041,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.041,"twentyDayClose":0.047,"sixtyDayClose":0.039},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSX.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650522331","title":"How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific (BSX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2650522331","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650522331?lang=en_us&edition=fundamental","pubTime":"2026-07-12 04:28","pubTimestamp":1783801734,"startTime":"0","endTime":"0","summary":"In early July 2026, Boston Scientific voluntarily recalled a single Intera Oncology INTERA 3000 Hepatic Artery Infusion Pump (Class II, Serial Number 20175) in the US after identifying potential leakage from the pump through the catheter, with the recall now classified as completed.\nA separate earnings update saw management cut 2026 guidance amid weakness in WATCHMAN, Electrophysiology, and Urology, while expressing confidence that upcoming product launches could support results in 2027 and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-boston-scientifics-2026-guidance-cut-and-pump-recall-at","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-boston-scientifics-2026-guidance-cut-and-pump-recall-at","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B4R5TH58.HKD","LU0114720955.EUR","BSX.AU","LU0432979614.USD","BK4504","LU2362540622.SGD","LU1989772923.USD","LU2362541273.HKD","LU1989764748.USD","LU2244417387.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0882574055.USD","BK4581","LU1057294990.SGD","LU0266013472.USD","LU1291159041.SGD","IE0009355771.USD","SG9999013999.USD","LU0267386448.USD","LU2506952170.USD","LU1720051108.HKD","LU1791710400.SGD","LU2265009873.SGD","LU2491050154.USD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2087625088.SGD","SGXZ57979304.SGD","BK4082","LU0823417737.USD","LU0345769128.USD","IE0002141913.USD","LU0122379950.USD","LU2491049909.HKD","LU2506951875.HKD","LU0011850046.USD","BSX","LU0238689110.USD","LU0823417653.USD","BK4585","LU0225283273.USD","LU1153585028.USD","IE00BFTCPJ56.SGD","LU0950375773.USD","LU1366192091.USD","LU1804176565.USD","LU0353189763.USD","LU1023059063.AUD","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650294186","title":"Is Boston Scientific (BSX) Undervalued Following Its Russell Growth Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650294186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650294186?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:43","pubTimestamp":1783673028,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has recently been dropped from several Russell growth benchmarks, a broad index reshuffle that can affect how index funds hold the stock and may change short term trading volumes.\nSee our latest analysis for Boston Scientific.\nOver the past year Boston Scientific has shifted from strong multi year gains to clear selling pressure, with the share price at $44.99 and a 90 day share price return down 27.19% and a 1 year total shareholder return down 56.68%. Recent index...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-undervalued-following-its-russell-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-undervalued-following-its-russell-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0267386448.USD","BK4082","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2087625088.SGD","BSX","LU2491050154.USD","LU1989772923.USD","SG9999001176.SGD","LU0528227936.USD","LU1291159041.SGD","SG9999001176.USD","LU2244417387.USD","LU0345769128.USD","LU0011850046.USD","LU0225283273.USD","LU0353189763.USD","LU1366192091.USD","LU1989771016.USD","LU0950375773.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU2265009873.SGD","LU2506951958.HKD","LU1548497426.USD","LU2242649171.HKD","LU1791710582.SGD","BK4588","LU0882574055.USD","IE00B2B36J28.USD","BSX.AU","BK4504","LU0823417653.USD","LU1720051108.HKD","LU2491050071.SGD","LU2506952170.USD","LU1989764664.SGD","LU0238689110.USD","LU1983299246.USD","LU2362541273.HKD","BK4585","BK4581","LU2112291526.USD","LU2506951875.HKD","LU0823416689.USD","LU0251132253.USD","LU2362540622.SGD","LU0345769631.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650790572","title":"Australia's Anson Resources Gains Most in a Month on U.S Lithium Operations Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2650790572","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650790572?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:27","pubTimestamp":1783650461,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Anson Resources gains most in a month on U.S lithium operations approval** Shares of Australia's Anson ResourcesASN.AXrise as much as 11.63% to A$0.048inbiggest intraday pct gainin ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL6N43C04M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX.AU","ASN.AU","BK7095","BK7504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901170","title":"ASX Penny Stocks To Watch In July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901170?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:05","pubTimestamp":1783649103,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a flat open, with modest movements not quite enough to propel the ASX 200 into positive territory, despite recoveries in the U.S. and Europe. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong financials and a clear growth trajectory, these stocks can present valuable prospects for those looking to explore this...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3031000-choice2-main-header/1585186655644","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3031000-choice2-main-header/1585186655644"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-gwa/gwa-group-shares/news/asx-penny-stocks-to-watch-in-july-2026-4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-gwa/gwa-group-shares/news/asx-penny-stocks-to-watch-in-july-2026-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7012","BK7062","GWA.AU","BK7095","BSX.AU","QAL.AU","BK7121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645510044","title":"How Softer 2026 Guidance and EP Share Shifts At Boston Scientific (BSX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2645510044","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645510044?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:20","pubTimestamp":1782109207,"startTime":"0","endTime":"0","summary":"Earlier in 2026, Boston Scientific reported solid Q1 results with 11.6% year-over-year revenue growth, but its initial 2026 guidance came in below market expectations and highlighted slowing momentum in its electrophysiology business.\nThe electrophysiology slowdown, where Medtronic appears to be gaining share, raises questions about Boston Scientific’s competitive positioning in a segment that has been an important growth contributor.\nWe’ll now examine how softer guidance and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-softer-2026-guidance-and-ep-share-shifts-at-boston-scien","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/how-softer-2026-guidance-and-ep-share-shifts-at-boston-scien","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1548497426.USD","LU0432979614.USD","LU0345769631.USD","LU2087625088.SGD","LU2242649171.HKD","LU0353189763.USD","LU1791710582.SGD","IE00BJJMRZ35.SGD","LU1989772923.USD","LU2112291526.USD","BK4504","LU0187121727.USD","LU1366192091.USD","LU0266013472.USD","IE0002141913.USD","LU2491049909.HKD","BK4585","LU2491050071.SGD","LU0114720955.EUR","LU2362541513.USD","LU1720051108.HKD","LU0823417653.USD","SGXZ57979304.SGD","LU1153585028.USD","LU2362541273.HKD","LU0882574055.USD","BK7095","LU2506952097.USD","LU2265009873.SGD","LU0823416689.USD","LU0251132253.USD","LU0345769128.USD","LU1023059063.AUD","LU1989771016.USD","BK4082","LU0138981039.USD","IE00B4R5TH58.HKD","LU1804176565.USD","IE00BFTCPJ56.SGD","LU1989764748.USD","BSX","LU0011850046.USD","LU0353189680.USD","BSX.AU","LU2244417387.USD","BK4213","SG9999001176.USD","LU1989764664.SGD","LU2506951875.HKD","EP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065423","title":"Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065423","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644065423?lang=en_us&edition=fundamental","pubTime":"2026-06-20 02:48","pubTimestamp":1781894927,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment.\nSee our latest analysis for Boston Scientific.\nAt a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-could-be-542-undervalued-after-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-could-be-542-undervalued-after-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1989772923.USD","LU1153585028.USD","LU1718418525.SGD","LU2357305700.SGD","LU0950375773.USD","IE0009355771.USD","LU0011850046.USD","LU0187121727.USD","LU0048584097.USD","LU0882574055.USD","LU1291159041.SGD","LU0114720955.EUR","LU2244417387.USD","LU2362541273.HKD","LU1989764664.SGD","LU1057294990.SGD","LU2506951958.HKD","BSX.AU","LU0353189680.USD","LU1791710582.SGD","LU0823417737.USD","LU1989764748.USD","LU2265009873.SGD","LU0266013472.USD","BK4581","LU0345769631.USD","IE0002141913.USD","BSX","SGXZ57979304.SGD","LU2112291526.USD","LU2506951875.HKD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU2324357040.USD","LU2362540622.SGD","LU1023059063.AUD","LU1989771016.USD","LU0238689110.USD","LU0345769128.USD","LU0138981039.USD","LU0225283273.USD","LU0267386448.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","LU2087625088.SGD","LU1989772840.SGD","BK4585","LU2506952170.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640341311","title":"Is Boston Scientific (BSX) Quietly Rebalancing From Structural Heart To Coronary Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640341311","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640341311?lang=en_us&edition=fundamental","pubTime":"2026-06-04 13:28","pubTimestamp":1780550897,"startTime":"0","endTime":"0","summary":"In recent weeks, Boston Scientific reported solid year-on-year revenue growth but issued softer guidance, as management flagged slowing U.S. Watchman device sales and intensifying cardiac market competition, prompting some analysts to downgrade the company. \nAt the same time, the company announced positive pivotal FRACTURE IDE trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, highlighting how strengths in its coronary portfolio may balance weakness in parts of...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-quietly-rebalancing-from-structural","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientific-bsx-quietly-rebalancing-from-structural","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0077335932.USD","LU1718418525.SGD","BSX.AU","LU0353189680.USD","LU0187121727.USD","LU0251132253.USD","LU0432979614.USD","LU2242649171.HKD","BK4504","LU2362540622.SGD","SG9999001176.SGD","LU1989772923.USD","LU2362541273.HKD","LU1989764748.USD","LU2491050071.SGD","LU1057294990.SGD","LU0882574055.USD","BK4581","IE0009355771.USD","LU1548497426.USD","LU1989764664.SGD","LU0267386448.USD","LU1989772840.SGD","IE00B2B36J28.USD","LU1720051108.HKD","LU1791710400.SGD","LU2491050154.USD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2087625088.SGD","LU2357305700.SGD","BK4082","LU0345769128.USD","IE0002141913.USD","LU2506951875.HKD","LU0011850046.USD","BSX","LU0048584097.USD","LU0345769631.USD","LU0823416689.USD","LU0823417653.USD","LU0528227936.USD","LU2506951958.HKD","LU1989771016.USD","LU1153585028.USD","LU0225283273.USD","IE00BFTCPJ56.SGD","LU0950375773.USD","LU1023059063.AUD","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640385960","title":"Blackstone Minerals Ltd-Key Consultants Appointed as Mankayan Pfs Gains Moment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640385960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640385960?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:21","pubTimestamp":1780352495,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUE7KGFVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","BSX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639161094","title":"Assessing Boston Scientific (BSX) Valuation After Strong SEISMIQ 4CE Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2639161094","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639161094?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:23","pubTimestamp":1780014208,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) is back in focus after reporting strong pivotal trial data for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, which met key safety and effectiveness goals in patients with severely calcified coronary artery disease.\nSee our latest analysis for Boston Scientific.\nThe strong SEISMIQ 4CE trial update comes against a weak recent trading backdrop, with the share price down 16% over 30 days and the 1-year total shareholder return down 53%, although the 5-year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/assessing-boston-scientific-bsx-valuation-after-strong-seism","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/assessing-boston-scientific-bsx-valuation-after-strong-seism","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2506951875.HKD","BSX.AU","LU0345769128.USD","IE00BFTCPJ56.SGD","LU1989772840.SGD","LU0048584097.USD","LU2112291526.USD","LU0823417737.USD","LU0225283273.USD","BK4585","LU2491049909.HKD","LU2362541273.HKD","LU2506952097.USD","SG9999001176.SGD","BSX","LU2362541513.USD","LU0353189680.USD","LU1057294990.SGD","LU0823417653.USD","LU1989772923.USD","IE0009355771.USD","LU0823416689.USD","IE00B2B36J28.USD","LU0267386448.USD","SGXZ57979304.SGD","LU1989764748.USD","LU0114720955.EUR","LU1548497426.USD","BK4504","LU1791710400.SGD","BK4581","LU2244417387.USD","LU1718418525.SGD","LU1791710582.SGD","LU1720051017.SGD","LU1804176565.USD","LU1366192091.USD","BK4082","LU0138981039.USD","LU1989764664.SGD","LU2357305700.SGD","LU0187121727.USD","LU0432979614.USD","LU0077335932.USD","IE00BJJMRZ35.SGD","LU0011850046.USD","SG9999013999.USD","LU0238689110.USD","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692754","title":"Boston Scientific's 2026 Guidance Intact Despite Watchman Headwind, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692754","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692754?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:57","pubTimestamp":1779983875,"startTime":"0","endTime":"0","summary":"Boston Scientific  shares fell Wednesday after Chief Executive Mike Mahoney's comments about flat sequential US revenue for the Watchman device in Q2 and potentially in Q3, but the company's 2026 guidance remains intact, RBC Capital Markets said in a note.The investment firm said the stroke prevention device's performance reflects continued decline in standalone procedures, although this was partially offset by an increase in concomitant procedures.RBC highlighted that Boston Scientific's organic revenue growth guidance of 5% to 7% year on year in Q2, and 6.5% to 8% for 2026, including the flat outlook for Watchman, is still in place. Management also expects the Watchman device to \"return to hypergrowth\" backed by factors like a label change submitted to the US Food and Drug Administration, as well as patient education.The investment firm said it continues to believe in the long-term growth contribution from Watchman based on checks despite the near-term trends.RBC Capital Markets has ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1983299246.USD","LU0138981039.USD","IE00B2B36J28.USD","LU0266013472.USD","BK7095","LU1061106388.HKD","LU2357305700.SGD","LU0882574055.USD","LU1791710400.SGD","IE00BJT1NW94.SGD","LU0353189680.USD","LU1804176565.USD","LU0251132253.USD","LU0353189763.USD","LU0029864427.USD","LU0823416689.USD","LU2362541273.HKD","LU0128525929.USD","LU2506952170.USD","BK4581","LU1989764664.SGD","LU1057294990.SGD","LU2362541513.USD","LU0122379950.USD","LU0077335932.USD","LU1791710582.SGD","BSX.AU","LU1267930573.SGD","LU2244417387.USD","LU0823417737.USD","IE00B4R5TH58.HKD","LU0950375773.USD","SG9999001176.SGD","LU1989772923.USD","LU0011850046.USD","BK4207","LU2087625088.SGD","BSX","LU2506951958.HKD","BK4588","LU2362540622.SGD","IE0002141913.USD","LU2506951875.HKD","LU2242649171.HKD","LU0187121727.USD","SG9999013999.USD","LU0823417653.USD","LU0432979614.USD","LU0528227936.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638451680","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2638451680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638451680?lang=en_us&edition=fundamental","pubTime":"2026-05-28 02:07","pubTimestamp":1779905246,"startTime":"0","endTime":"0","summary":"Zscaler  shares plunged 31% intraday after the company issued a fiscal Q4 revenue outlook that missed analysts' expectations late on Tuesday.The stock remains in the penalty box until further evidence of traction emerges in the security operations business, new sales leader roles are filled, and the operating structure improves, Morgan Stanley said in a research report.Shares sank 31% following a surge in intraday trading volume to over 23.9 million from a daily average of about 3.05 million.Verra Mobility  cut its 2026 outlook following car rental firm Avis Budget's  decision to terminate a contract with the company, effective September.Shares slumped 71% as intraday trading volume advanced to more than 56.7 million from a daily average of about 1.7 million.Boston Scientific's  Chief Executive Mike Mahoney said at an industry conference that this year has been \"a bit more of a challenge\" than anticipated.Stifel cut its price target to $75 from $85 while keeping its buy rating. Goldman","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2286300806.USD","IE0002141913.USD","BK4560","SGXZ57979304.SGD","LU1291159041.SGD","CAR.AU","BK4588","LU0251132253.USD","LU2362541513.USD","LU1983299246.USD","LU1989764664.SGD","LU0114720955.EUR","LU0823417737.USD","ZS","BK4106","SG9999013999.USD","BK4516","LU0006306889.USD","LU0950375773.USD","LU1720051017.SGD","VRRM","LU0158827781.USD","LU1815336091.USD","IE00BJT1NW94.SGD","BSX.AU","LU0528227936.USD","LU2506952097.USD","LU0122379950.USD","LU0882574139.USD","LU2491050071.SGD","BSX","LU0011850046.USD","LU1363072403.SGD","LU2264538146.SGD","BK4534","BK4581","CAR","LU0210528500.USD","LU1718418525.SGD","LU2125909759.SGD","LU2362541273.HKD","BK4097","LU0158827948.USD","LU0053671581.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1804176565.USD","LU2506952170.USD","IE00BJJMRZ35.SGD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638817516","title":"Boston Scientific Shares Fall as CEO Flags Short-Term Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2638817516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638817516?lang=en_us&edition=fundamental","pubTime":"2026-05-27 23:21","pubTimestamp":1779895316,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) shares fell 9% in Wednesday trading after Chief Executive Mike Mahoney said this year has been \"a bit more of a challenge\" than anticipated.Mahoney said at an industry conferen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2491050071.SGD","LU2506951958.HKD","SG9999013999.USD","LU1718418525.SGD","LU1153585028.USD","LU0823417653.USD","LU0267386448.USD","BSX","LU0823417737.USD","LU1791710400.SGD","LU1989764664.SGD","LU1720051017.SGD","LU2357305700.SGD","BK4504","LU1720051108.HKD","LU2491050154.USD","LU0345769128.USD","LU1366192091.USD","LU1061106388.HKD","LU0823416689.USD","LU0048584097.USD","LU2242649171.HKD","SG9999001176.SGD","LU2506952097.USD","SG9999001176.USD","LU0077335932.USD","LU1989772840.SGD","LU2506951875.HKD","LU0187121727.USD","IE00B2B36J28.USD","LU1983299246.USD","LU2112291526.USD","LU2087625088.SGD","LU0138981039.USD","LU2324357040.USD","LU1989772923.USD","LU0528227936.USD","LU0122379950.USD","BSX.AU","IE00BFTCPJ56.SGD","LU0353189680.USD","LU0950375773.USD","IE00B4R5TH58.HKD","LU2362540622.SGD","SGXZ57979304.SGD","BK4588","BK7095","LU0882574055.USD","LU0238689110.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636865778","title":"Sector Update: Healthcare Stocks Rise Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636865778?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:02","pubTimestamp":1779213753,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) incre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BWXC8680.SGD","BK4550","IE0009355771.USD","IE0034235295.USD","JPX","LU1989772840.SGD","RLAY","LU2362541513.USD","BK4585","LABU","LU0234572021.USD","BSX","LU0353189763.USD","LU1244550494.USD","BK4139","HCSG","LU1057294990.SGD","LU1718418525.SGD","BK4516","LU0203347892.USD","BK4581","BSX.AU","LU1791710582.SGD","LU2746668461.USD","LU2746668974.SGD","LU2265009873.SGD","IBB","LU2023250843.SGD","XLV","LU2505996509.AUD","XBI","LU2054465674.USD","IE00BJTD4N35.SGD","IE00B4R5TH58.HKD","LU0106261372.USD","MTVA","LU0203345920.USD","LU2491049909.HKD","IE00B1XK9C88.USD","LU0208291251.USD","LU1670627923.USD","TLSA","LU0149725797.USD","LU0640476718.USD","LU2237443978.SGD","LU2552382058.USD","JPMO","LU0266013472.USD","LU0689472784.USD","JPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636533098","title":"Boston Scientific Catheter Says Trial Meets Safety, Effectiveness Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2636533098","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636533098?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:21","pubTimestamp":1779189688,"startTime":"0","endTime":"0","summary":"Boston Scientific  said Tuesday that a clinical trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.The study of 420 patients demonstrated a 93.3% rate of freedom from major adverse cardiac events at 30 days alongside a 93.7% procedural success rate, the company said.Physicians achieved complete stent delivery success and a 94.2% average expansion rate at the most calcified arterial segments using the device, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2087625088.SGD","LU0353189680.USD","LU1061106388.HKD","SGXZ57979304.SGD","BSX","LU0122379950.USD","LU2491050154.USD","LU0187121727.USD","LU1989772923.USD","SG9999001176.SGD","LU1718418525.SGD","LU0528227936.USD","LU1291159041.SGD","SG9999001176.USD","LU1153585028.USD","LU0345769128.USD","LU1804176565.USD","LU0353189763.USD","LU1366192091.USD","LU2357305700.SGD","LU0950375773.USD","LU2265009873.SGD","LU2506951958.HKD","LU2362541513.USD","LU2506952097.USD","LU1548497426.USD","LU2242649171.HKD","LU1791710582.SGD","LU0882574055.USD","IE0002141913.USD","BSX.AU","LU0823417653.USD","LU1720051108.HKD","LU2491050071.SGD","LU1989764664.SGD","IE0009355771.USD","LU0138981039.USD","LU0238689110.USD","LU2362541273.HKD","LU0048584097.USD","BK4585","BK4581","LU1720051017.SGD","LU2112291526.USD","LU0251132253.USD","LU0345769631.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636934005","title":"Boston Scientific Makes Third Attempt at TAVR Market, Needham Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2636934005","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636934005?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:03","pubTimestamp":1779131013,"startTime":"0","endTime":"0","summary":"Boston Scientific  is making its third attempt at the Transcatheter Aortic Valve Replacement market with its $1.5 billion investment in MiRus, Needham said in a note Monday.Earlier, Boston said it secured a 34% stake in MiRus that focuses on cardiovascular and orthopedic diseases treatment, including the SIEGEL Balloon Expandable TVAR system.\"We believe that BSX's third attempt with TAVR could provesuccessful and enable it to capture meaningful market share if the STAR trial meets its endpoints and SIEGEL's differentiated design and features resonate with physicians,\" the note said.LOTUS TAVR and ACURATE TAVR were removed from the market after each had various issues, the report added.\"Importantly, the deal's structure limits BSX's risk to its initial $1.5B investment,\" the report said.Needham reiterated its buy rating with a $77 price target.Price: 55.57, Change: +2.89, Percent Change: +5.49","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1057294990.SGD","LU1804176565.USD","BK4588","BK4581","IE00B2B36J28.USD","LU1718418525.SGD","LU1989772840.SGD","SG9999001176.SGD","LU0251132253.USD","LU2362541513.USD","LU0882574055.USD","LU2506951875.HKD","LU0528227936.USD","LU1791710400.SGD","LU0823416689.USD","BSX.AU","LU1061106388.HKD","LU0345769128.USD","BK4585","LU0138981039.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU1720051108.HKD","LU1548497426.USD","BSX","LU2242649171.HKD","LU1791710582.SGD","LU2491050154.USD","IE0009355771.USD","LU0432979614.USD","LU0950375773.USD","LU2087625088.SGD","LU0011850046.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","LU0048584097.USD","LU2491049909.HKD","BK4504","LU0122379950.USD","LU2362540622.SGD","LU0225283273.USD","BK4082","LU1366192091.USD","LU1989764664.SGD","LU2357305700.SGD","LU2265009873.SGD","LU0353189680.USD","LU0114720955.EUR","LU2491050071.SGD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633127485","title":"Penumbra is a 'Strong' Strategic fit for Boston Scientific, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2633127485","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633127485?lang=en_us&edition=fundamental","pubTime":"2026-05-08 01:32","pubTimestamp":1778175151,"startTime":"0","endTime":"0","summary":"Penumbra  is a \"strong\" strategic and financial fit for Boston Scientific , which expects the deal to be accretive to its profitable growth profile, RBC Capital Markets said in Wednesday research report.Penumbra delivered an upside revenue surprise in Q1 driven by outperformance in embolization and access segments, while thrombectomy sales lagged, analysts wrote.Q1 sales were primarily attributable to higher sales volume in the US due to further market penetration of products while price remained stable, according to the note.The brokerage said it reiterated its sector perform rating on the stock and price target of $374 per share, pending the deal close in H2.Price: 324.81, Change: +0.62, Percent Change: +0.19","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362540622.SGD","LU2357305700.SGD","BSX.AU","IE0002141913.USD","LU2491050154.USD","BK7095","LU0345769128.USD","BK4082","LU0345769631.USD","LU2506951958.HKD","BK4585","LU1989772923.USD","BK4504","BK4581","BK4588","LU2112291526.USD","LU0823417737.USD","LU2242649171.HKD","LU1718418525.SGD","LU0823417653.USD","SGXZ57979304.SGD","LU0187121727.USD","LU2362541273.HKD","LU0114720955.EUR","LU1291159041.SGD","BK4548","LU0353189763.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU1989771016.USD","PEN","BSX","LU0432979614.USD","LU1804176565.USD","LU2362541513.USD","LU1153585028.USD","LU2506952170.USD","LU1061106388.HKD","LU1720051108.HKD","LU0267386448.USD","LU2265009873.SGD","LU0077335932.USD","SG9999001176.SGD","LU1548497426.USD","LU2087625088.SGD","LU0353189680.USD","PEN.AU","LU1366192091.USD","LU0011850046.USD","LU2244417387.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632322779","title":"Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2632322779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632322779?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:19","pubTimestamp":1777889953,"startTime":"0","endTime":"0","summary":"In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE pulsed field ablation platform, WATCHMAN left atrial appendage closure devices, and EMBLEM MRI subcutaneous defibrillator.\nAt the same time, multiple securities class actions were filed alleging misleading disclosures about electrophysiology growth, creating a contrast between the company’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0122379950.USD","LU0345769128.USD","SGXZ57979304.SGD","LU0353189680.USD","LU0432979614.USD","IE0009355771.USD","BK4581","LU2362540622.SGD","LU2506952170.USD","LU0251132253.USD","LU1023059063.AUD","LU1366192091.USD","LU2087625088.SGD","LU0345769631.USD","LU0238689110.USD","LU1718418525.SGD","LU2491050071.SGD","IE00B2B36J28.USD","LU1291159041.SGD","BSX.AU","IE00BJJMRZ35.SGD","BK4213","LU0114720955.EUR","EP","LU1153585028.USD","LU0823416689.USD","IE0002141913.USD","LU0077335932.USD","LU1548497426.USD","BSX","BK4504","LU2244417387.USD","LU0528227936.USD","LU2362541513.USD","LU0187121727.USD","LU0011850046.USD","IE00B4R5TH58.HKD","LU1989771016.USD","LU2265009873.SGD","LU0950375773.USD","LU1061106388.HKD","BK7095","LU2491049909.HKD","LU2112291526.USD","LU0882574055.USD","LU0266013472.USD","LU2491050154.USD","LU2324357040.USD","SG9999013999.USD","LU2506951958.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629859813","title":"Boston Scientific 2026 Guidance Cut 'Prudent,' Q2 Trough Expected, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2629859813","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629859813?lang=en_us&edition=fundamental","pubTime":"2026-04-24 00:00","pubTimestamp":1776960022,"startTime":"0","endTime":"0","summary":"Boston Scientific  posted Q1 sales and earnings per share beats alongside a \"prudent\" guidance cut, with Q2 expected to be the trough quarter, RBC Capital Markets said in a note Wednesday.The analysts said management lowered 2026 organic growth outlook to 6.5% to 8% due to \"unanticipated headwinds\" and \"changing business patterns,\" though many investors already expected a reset, including those who believed the company could make the numbers to reset the base.The analysts called Q1 a \"clearing event,\" with Boston Scientific reporting Electrophysiology growing 21.7% year-over-year on an organic basis versus 18.5% consensus, while Watchman grew 18.8% versus 21.5% consensus, broadly in line with expectations.\"Looking ahead, we view Q2 as a trough quarter  with improving growth thereafter aided by new products, improvement in base businesses, and Watchman growth in low double digits. We would be buyers at current valuations,\" the analysts said.RBC reiterated its outperform rating on Boston","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BSX.AU","LU0528227936.USD","LU1153585028.USD","LU2506951875.HKD","IE00BJT1NW94.SGD","LU0238689110.USD","LU1023059063.AUD","LU0077335932.USD","LU0882574055.USD","BK4585","LU0251132253.USD","LU2491050154.USD","LU1057294990.SGD","LU2244417387.USD","BSX","IE00BFTCPJ56.SGD","LU0187121727.USD","LU1291159041.SGD","SGXZ57979304.SGD","BK4581","LU1791710582.SGD","LU2362541273.HKD","LU2506952097.USD","SG9999001176.USD","LU2265009873.SGD","LU1989772840.SGD","LU2242649171.HKD","BK7095","LU0823416689.USD","SG9999013999.USD","LU1366192091.USD","LU1989772923.USD","LU1718418525.SGD","LU2506952170.USD","LU0266013472.USD","LU0823417737.USD","LU0048584097.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","LU1989764664.SGD","LU2362541513.USD","LU1548497426.USD","LU2087625088.SGD","LU0950375773.USD","LU0345769128.USD","LU0353189680.USD","LU1989764748.USD","IE0009355771.USD","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017525","title":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.34 to $3.41, vs. FactSet Est of $3.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017525","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017525?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:33","pubTimestamp":1776854034,"startTime":"0","endTime":"0","summary":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.34 to $3.41, vs. FactSet Est of $3.45","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BSX","BSX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629732066","title":"A Look At Boston Scientific (BSX) Valuation After Recent Share Price Weakness And Penumbra Deal Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2629732066","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629732066?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:16","pubTimestamp":1776809810,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has drawn investor attention after recent share price weakness, with the stock showing negative returns over the past month and past 3 months, prompting closer scrutiny of its valuation and fundamentals.\nSee our latest analysis for Boston Scientific.\nThat recent 14.34% 1 month share price decline and 37.16% year to date share price return have pulled Boston Scientific back from earlier gains, even as the 3 year total shareholder return of 16.45% and 5 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/a-look-at-boston-scientific-bsx-valuation-after-recent-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/a-look-at-boston-scientific-bsx-valuation-after-recent-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1791710582.SGD","LU0823416689.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2357305700.SGD","LU1989764664.SGD","LU1720051017.SGD","LU2265009873.SGD","LU0225283273.USD","LU1804176565.USD","IE00B2B36J28.USD","LU0048584097.USD","BK7095","LU0882574055.USD","SG9999001176.USD","BSX","LU0823417653.USD","LU2506951875.HKD","LU1989772840.SGD","BSX.AU","LU0251132253.USD","LU0266013472.USD","LU0432979614.USD","BK4082","BK4588","LU0187121727.USD","LU0528227936.USD","LU1718418525.SGD","LU2362540622.SGD","LU1291159041.SGD","SG9999013999.USD","LU1989771016.USD","LU2506952170.USD","BK4548","LU0345769128.USD","BK4504","LU1548497426.USD","LU2087625088.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","PEN","LU1061106388.HKD","LU0077335932.USD","SG9999001176.SGD","LU2112291526.USD","LU2506952097.USD","IE0009355771.USD","LU0353189680.USD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}